Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Chika Iwamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7139-325X; OpenAlex author ID A5049148592. Sources: OpenAlex.

Their work

Papers
22
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2017: 2 papers · 2018: 2 papers · 2019: 3 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 5 papers · 2025: 3 papers

Papers 22

  1. Identification of cold tumor induction-related markers in pancreatic cancer and the clinical implication of PCDH7. Co-author DOI 10.1007/s00432-025-06095-z↗
  2. uPAR expression in M-MDSCs under high LDHA activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-29823-4↗
  3. Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. Co-author DOI 10.3389/fimmu.2025.1571182↗
  4. Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cance… Co-author DOI 10.1158/0008-5472.can-24-0830↗
  5. Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells. Co-author DOI 10.1186/s13046-024-03060-5↗
  6. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03178-6↗
  7. Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03192-8↗
  8. [Microbiome in the Therapy for the Pancreatic Cancer]. Co-author PMID 39009514↗
  9. Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front. Co-author DOI 10.1007/s00432-022-04554-5↗
  10. Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1-CXCR2 axis. Co-author DOI 10.1111/cas.15901↗
  11. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. Co-author DOI 10.1186/s13046-022-02301-9↗
  12. Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2021.04.013↗
  13. New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth. Co-author DOI 10.1016/j.pan.2021.04.002↗
  14. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. Co-author DOI 10.1371/journal.pone.0228015↗
  15. Neutrophil extracellular traps promote liver micrometastasis in pancreatic ductal adenocarcinoma via the activation of cancer‑associated fibroblasts. Co-author DOI 10.3892/ijo.2019.4951↗
  16. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis. Co-author DOI 10.1007/s00432-019-02860-z↗
  17. Robust 3D image reconstruction of pancreatic cancer tumors from histopathological images with different stains and its quantitative performance evaluation. Co-author DOI 10.1007/s11548-019-02019-8↗
  18. Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion. Co-author DOI 10.1016/j.canlet.2018.12.005↗
  19. Pancreatic stellate cells reorganize matrix components and lead pancreatic cancer invasion via the function of Endo180. Co-author DOI 10.1016/j.canlet.2017.10.010↗
  20. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2018.03.031↗
  21. Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mi… Co-author DOI 10.1053/j.gastro.2017.01.010↗
  22. Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancr… Co-author DOI 10.18632/oncotarget.15430↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kohei Nakata · 21 shared papers, 2017–2025 · strength 2.74
  2. Kenoki Ohuchida · 21 shared papers, 2017–2025 · strength 2.63
  3. Naoki Ikenaga · 13 shared papers, 2021–2025 · strength 2.18
  4. Toshiya Abe · 14 shared papers, 2017–2025 · strength 1.73
  5. Yoshinao Oda · 13 shared papers, 2017–2025 · strength 1.67
  6. Masafumi Nakamura · 13 shared papers, 2017–2024 · strength 1.58
  7. Koki Oyama · 7 shared papers, 2023–2025 · strength 1.22
  8. Koji Shindo · 9 shared papers, 2019–2024 · strength 1.04
  9. Chikanori Tsutsumi · 5 shared papers, 2024–2025 · strength 0.92
  10. Masataka Hayashi · 5 shared papers, 2023–2024 · strength 0.87
  11. Tomohiko Shinkawa · 6 shared papers, 2020–2025 · strength 0.84
  12. Noboru Ideno · 5 shared papers, 2022–2025 · strength 0.82
  13. Pingshan Zhong · 5 shared papers, 2021–2024 · strength 0.75
  14. Kazuhiro Koikawa · 8 shared papers, 2017–2024 · strength 0.72
  15. Yuki Mochida · 4 shared papers, 2022–2025 · strength 0.68
  16. Yoshihiro Miyasaka · 9 shared papers, 2017–2021 · strength 0.67
  17. Takao Ohtsuka · 9 shared papers, 2017–2021 · strength 0.67
  18. Haizhen Luo · 4 shared papers, 2023–2024 · strength 0.63
  19. Hideya Onishi · 3 shared papers, 2024–2025 · strength 0.55
  20. Bo Zhang · 3 shared papers, 2023–2025 · strength 0.55
  21. Shin Kibe · 6 shared papers, 2018–2023 · strength 0.54
  22. Takashi Morisaki · 3 shared papers, 2024–2025 · strength 0.51
  23. Shin Takesue · 7 shared papers, 2017–2020 · strength 0.51
  24. Takashi Okumura · 7 shared papers, 2017–2021 · strength 0.49
  25. Yohei Ando · 6 shared papers, 2018–2021 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.